Related Experiment Video
Updated: Nov 9, 2025
Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Weathering the storm: COVID-19 infection in patients with hematological malignancies
Lin-Qin Wang1,2,3,4, Elaine Tan Su Yin1,2,3,4, Guo-Qing Wei1,2,3,4
1Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
Insights
Patients with hematological malignancies (HMs) face higher risks and worse outcomes with COVID-19. This review details clinical issues and management strategies for this vulnerable group.
Area of Science:
- Infectious Diseases
- Oncology
- Internal Medicine
Background:
- COVID-19, caused by SARS-CoV-2, is a rapidly spreading global pandemic.
- Patients with hematological malignancies (HMs) have compromised immune systems, increasing their vulnerability to infections.
- Comorbidities and chronic diseases in COVID-19 patients are linked to poor treatment outcomes.
Purpose of the Study:
- To review and analyze the specific clinical manifestations of COVID-19 in patients with hematological malignancies.
- To outline customized management strategies and interventions for this high-risk patient cohort.
Main Methods:
- This study is a review of existing literature and clinical data.
- Analysis of specific clinical presentations in patients with coexisting COVID-19 and HMs.
- Synthesis of current knowledge on management and interventions.
Main Results:
- Patients with HMs present unique clinical challenges when infected with SARS-CoV-2.
- Immunosuppression in HM patients exacerbates COVID-19 severity and prognosis.
- Tailored management approaches are crucial for improving outcomes in this population.
Conclusions:
- COVID-19 poses a significant threat to patients with hematological malignancies, necessitating specialized care.
- Understanding specific clinical manifestations is key to effective management.
- Customized interventions are vital to guide clinical practice and improve patient prognosis.
Abstract:
The coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a matter of months, this highly contagious novel virus has led to a global outbreak and is still spreading rapidly across continents. In patients with COVID-19, underlying chronic diseases and comorbidities are associated with dismal treatment outcomes. Owing to their immunosuppressive status, patients with hematological malignancies (HMs) are at an increased risk of infection and have a worse prognosis than patients without HMs. Accordingly, intensive attention should be paid to this cohort. In this review, we summarize and analyze specific clinical manifestations for patients with coexisting COVID-19 and HMs. Furthermore, we briefly describe customized management strategies and interventions for this susceptible cohort. This review is intended to guide clinical practice.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:01Regulation of Hematopoietic Stem Cells
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...